Association of chronic baseline prostate inflammation with lower tumor grade in men with prostate cancer on repeat biopsy.

Authors

null

Daniel M. Moreira

Mayo Clinic, Rochester, MN

Daniel M. Moreira , J. Curtis Nickel , Gerald L. Andriole , Ramiro Castro , Stephen J. Freedland

Organizations

Mayo Clinic, Rochester, MN, Queen's University, Kingston, ON, Canada, Washington Univ School of Medcn, St Louis, MO, GlaxoSmithKline, Bryn Mawr, PA, Cedars-Sinai Medical Center, Los Angeles, CA

Research Funding

No funding sources reported

Background: We have previously shown that chronic baseline prostate inflammation in an otherwise benign biopsy was associated with lower risk of prostate cancer in repeat prostate biopsies and lower tumor volumes for those who are diagnosed with cancer. In the present study, we evaluated whether baseline acute or chronic prostate inflammation among men with initial negative biopsies for prostate cancer was associated with cancer grade at the 2-year repeat prostate biopsy. Methods: Retrospective analysis of 889 men 50-75 years-old with negative baseline prostate biopsy and positive 2-year repeat biopsy for prostate cancer in the REDUCE study. Acute and chronic prostate inflammation (coded as present or absent) and cancer grade were determined by central pathology. The association of inflammation in baseline biopsies with 2-year repeat biopsy cancer grade (low-grade: Gleason scores 2-6 vs. high-grade: Gleason scores 7-10) was evaluated with t test, chi-squared test and logistic regression controlling for age, race, body-mass index (BMI), digital rectal exam (DRE), prostate volume, baseline pre-study PSA and treatment (dutasteride or placebo). Results: Chronic, acute inflammation and both were detected in 533 (60%), 12 (1%) and 85 (10%) baseline biopsies, respectively. Presence of acute and chronic inflammations were significantly associated with each other (P < 0.001). Patients with chronic inflammation had significantly larger prostates (P < 0.001). Both types of inflammation were unrelated to race, BMI, PSA or DRE. At 2-year biopsy, a total of 621 (70%) tumors were low-grade and 268 (30%) tumors were high-grade. In both uni- and multivariable analyses, men with baseline chronic inflammation had significantly less high-grade tumors (univariable OR = 0.64, 95% CI = 0.47-0.87, P = 0.004; multivariable OR = 0.68, 95% CI = 0.50-0.93, P = 0.016) than those without baseline chronic inflammation. Baseline acute inflammation was not associated with tumor grade. Conclusions: Among men undergoing repeat prostate biopsy 2 years after a negative baseline biopsy who all had cancer on the follow-up biopsy, the presence baseline chronic inflammation was associated with lower prostate cancer grade.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2016 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Localized Disease

Citation

J Clin Oncol 34, 2016 (suppl 2S; abstr 75)

DOI

10.1200/jco.2016.34.2_suppl.75

Abstract #

75

Poster Bd #

D13

Abstract Disclosures

Similar Abstracts

First Author: Vinay Mathew Thomas

First Author: Joshua Mabellos

Abstract

2023 ASCO Genitourinary Cancers Symposium

Correlation of tumor gene expression profile and gleason score (GS) in patients (pts) with metastatic prostate cancer.

First Author: Nicolas Sayegh